CN101406711B - Method for preparing galvanic deposit calcium phosphorus mineralized layer superfine fibre bone material - Google Patents
Method for preparing galvanic deposit calcium phosphorus mineralized layer superfine fibre bone material Download PDFInfo
- Publication number
- CN101406711B CN101406711B CN2008102021651A CN200810202165A CN101406711B CN 101406711 B CN101406711 B CN 101406711B CN 2008102021651 A CN2008102021651 A CN 2008102021651A CN 200810202165 A CN200810202165 A CN 200810202165A CN 101406711 B CN101406711 B CN 101406711B
- Authority
- CN
- China
- Prior art keywords
- bone material
- calcium
- solution
- bone
- electrospinning
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000463 material Substances 0.000 title claims abstract description 69
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 66
- 239000000835 fiber Substances 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 30
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 title claims description 8
- 208000004434 Calcinosis Diseases 0.000 title description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 32
- 238000001523 electrospinning Methods 0.000 claims abstract description 18
- 229920001410 Microfiber Polymers 0.000 claims abstract description 17
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 16
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 14
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 14
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 14
- 238000004070 electrodeposition Methods 0.000 claims abstract description 14
- 229920000642 polymer Polymers 0.000 claims abstract description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000011575 calcium Substances 0.000 claims abstract description 8
- 238000000151 deposition Methods 0.000 claims abstract description 6
- 238000005516 engineering process Methods 0.000 claims abstract description 6
- 239000011148 porous material Substances 0.000 claims abstract description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 5
- 238000013012 foaming technology Methods 0.000 claims abstract description 4
- 238000002386 leaching Methods 0.000 claims abstract description 4
- 230000007547 defect Effects 0.000 claims abstract description 3
- 230000008439 repair process Effects 0.000 claims abstract description 3
- 230000008021 deposition Effects 0.000 claims abstract 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 22
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 22
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 22
- 239000002131 composite material Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 229960001714 calcium phosphate Drugs 0.000 claims description 13
- 102000008186 Collagen Human genes 0.000 claims description 12
- 108010035532 Collagen Proteins 0.000 claims description 12
- 229920001436 collagen Polymers 0.000 claims description 11
- 229910052697 platinum Inorganic materials 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000009987 spinning Methods 0.000 claims description 7
- 229910001220 stainless steel Inorganic materials 0.000 claims description 7
- 239000010935 stainless steel Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 230000000975 bioactive effect Effects 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- -1 polyethylene Polymers 0.000 claims description 4
- 229920001059 synthetic polymer Polymers 0.000 claims description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 2
- 108010014258 Elastin Proteins 0.000 claims description 2
- 102000016942 Elastin Human genes 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 108010022355 Fibroins Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 2
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 229920002549 elastin Polymers 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 229920005615 natural polymer Polymers 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- QGHDLJAZIIFENW-UHFFFAOYSA-N 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxy-3-prop-2-enylphenyl)propan-2-yl]-2-prop-2-enylphenol Chemical group C1=C(CC=C)C(O)=CC=C1C(C(F)(F)F)(C(F)(F)F)C1=CC=C(O)C(CC=C)=C1 QGHDLJAZIIFENW-UHFFFAOYSA-N 0.000 claims 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 235000011114 ammonium hydroxide Nutrition 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 4
- 230000033558 biomineral tissue development Effects 0.000 abstract description 4
- 229910052791 calcium Inorganic materials 0.000 abstract description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 2
- 239000011574 phosphorus Substances 0.000 abstract description 2
- 238000004108 freeze drying Methods 0.000 abstract 1
- 229910003471 inorganic composite material Inorganic materials 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 230000005611 electricity Effects 0.000 description 24
- 239000000243 solution Substances 0.000 description 21
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 18
- 229920001432 poly(L-lactide) Polymers 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 5
- 239000000470 constituent Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000013590 bulk material Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 229910010272 inorganic material Inorganic materials 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010041 electrostatic spinning Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- CUXQLKLUPGTTKL-UHFFFAOYSA-M microcosmic salt Chemical compound [NH4+].[Na+].OP([O-])([O-])=O CUXQLKLUPGTTKL-UHFFFAOYSA-M 0.000 description 2
- 239000002121 nanofiber Substances 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920002749 Bacterial cellulose Polymers 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000005016 bacterial cellulose Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000000320 mechanical mixture Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013354 porous framework Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
Abstract
本发明涉及一种电沉积钙磷矿化层超细纤维骨材料的制备方法，首先采用静电纺丝在金属电极表面制备高聚物超细纤维，并以此为电化学沉积模板，采用恒电压或恒电流沉积技术在纤维表面沉积一层富含钙、磷的骨盐成分，矿化超细纤维经0.1～1.0mol/L NaOH溶液浸泡1～24h，矿化电纺纤维在10～40MPa压力下模压成块状，采用盐粒沥滤/气体发泡技术加工成孔隙率50～90％、孔径50～500μm的多孔骨材料，经冻干消毒后用于骨缺损修复。本发明所制备的多孔骨材料，具有较好的生物相容性，电化学沉积技术能够在较短的时间内制备出含有较高骨盐成分的有机-无机复合材料，制备时间短且条件温和。
The invention relates to a method for preparing superfine fiber bone material of electrodeposited calcium phosphate mineralization layer. Firstly, electrospinning is used to prepare high polymer superfine fiber on the surface of a metal electrode, and this is used as an electrochemical deposition template, and a constant voltage is used. Or constant current deposition technology deposits a layer of bone salt rich in calcium and phosphorus on the surface of the fiber, and the mineralized ultrafine fiber is soaked in 0.1-1.0mol/L NaOH solution for 1-24 hours, and the mineralized electrospun fiber is exposed to a pressure of 10-40MPa The lower mold is pressed into a block, and the porous bone material with a porosity of 50-90% and a pore diameter of 50-500 μm is processed by salt leaching/gas foaming technology, and is used for bone defect repair after freeze-drying and disinfection. The porous bone material prepared by the present invention has better biocompatibility, and the electrochemical deposition technology can prepare organic-inorganic composite materials containing higher bone salt components in a short period of time, and the preparation time is short and the conditions are mild .
Description
Technical field
The invention belongs to the preparation field of electric-woven super-fine fiber bone material, particularly relate to a kind of method for preparing of galvanic deposit calcium phosphorus mineralized layer superfine fibre bone material.
Background technology
The bone that causes because of a variety of causes is damaged, and the treatment that bone is damaged especially on a large scale remains a great problem that clinical medicine faces.Traditional exist as supply that the bone amount is limited, osteogenic ability is low, be prone to cause immunoreation and shortcoming such as spread disease, can't satisfy the requirement of clinical treatment from body or allogenic bone transplantation.
The biomineralization system that the main component of nature bone is made up of collagen fiber and hydroxyapatite (HA) crystal.Structurally; Nature bone is the composite organic-inorganic material with complicated hierarchy that is formed through HA by collagen fiber; With diameter is the main body frameworks of the collagen fiber of 100～2000nm by certain oriented formation bone; The filling of ultra-fine level HA crystal therebetween, its crystallization direction distributes along the major axis of collagen fiber.The unique multilevel hierarchy of nature bone makes it have mechanical properties such as high strength, high tenacity.Therefore simulate the formation mechanism of nature bone, adopt bionic method prepared composition, the structure organic and inorganic compound bone material similar with nature bone is the focus of bone material research always.
Adopting calcium, phosphorus inorganic salt and the macromolecular material composite methods close with the nature bone composition is the main thought of current preparation bionic scaffold material.As adopt phase detachment technique and rapid shaping technique HA and high polymer material to be processed into the composite of HA and high polymer through certain preparation method.But this material through direct compound preparation is the mechanical mixture of two kinds of materials, is difficult to form inorganic matter and the tight bonding of Organic substance on molecular level, can only be from composition and can not carry out bionical from structure.Another kind is an in-situ compositing; In polymer matrix inside or surface the composite that chemical reaction directly prepares HA and high polymer taking place through calcium salt and phosphate, can overcome direct compound tense HA and in polymer matrix, disperse uneven and the unmanageable shortcoming of composite structure.A kind of method for preparing that is used for the nm-crysal collagen-based calcium phosphate composition of bone reparation is disclosed like Chinese patent (application number 01136246.4); But this Compound Material Engineering intensity that is formed by self assembly merely is on the low side; Be difficult to obtain clinical practice widely, need to add new biology performance and the mechanical strength of component to improve material.In self assembly nHA/ collagen-based materials, add alginate and PLGA like Chinese patent (patent No. 01141901.6,01129699.2) respectively; Process the porous framework material; When keeping the good biocompatibility of self-assembled material; Improve the mechanical strength of material, had good clinical application prospect.
The static spinning superfine fibre can be simulated the ultrastructure of n cell epimatrix, is considered to a kind of ideal tissue substitute material.In recent years, many both at home and abroad researchs attempt adopting diverse ways to prepare organic and inorganic composite ultrafine fiber bone material.A kind of method is that bone ore deposit compositions such as HA are joined in the polymer solution, and directly electricity spins the HA composite ultrafine fiber.Though this method can be compound to bioactive molecules such as somatomedin in the material; But hydrophilic inorganic constituents and hydrophobic polymer phase capacitive are relatively poor; Need select special solvent for use or by surfactant; Inorganic constituents possibly reunited or disperse uneven in composite fibre, and the content of inorganic constituents is also owing to receiving the spinnability restriction to be difficult to improve (Kim HW, et al.J BiomedMater Res A 2006; 79 (3): 643-649.), the mechanical strength of material also can't reach requirements for clinical application (Sui G, et al.J Biomed Mater Res A 2007; 82 (2): 445-454.); Another kind method is that first electricity spins the polymer superfine fibre film, is placed among the SBF and soaks a period of time, makes HA be deposited on the superfine fibre surface preparation and goes out composite cellulosic membrane (Chen J, et al.J Biomed Mater Res A 2006; 79 (2): 307-17.).This method can overcome the mixing electricity and spin the inorganic constituents problem of uneven distribution that causes, also can improve the content of mineralogical composition.But mineralization process needs the long time, causes the degraded of composite fibre easily, is not suitable for the load of bioactive ingredients.
Summary of the invention
Technical problem to be solved by this invention provides a kind of method for preparing of galvanic deposit calcium phosphorus mineralized layer superfine fibre bone material; The porous bone material that the present invention is prepared; Be similar to the bone ore deposit composition that the nature bone forming process produces to a certain extent, have better biocompatibility.
The method for preparing of a kind of galvanic deposit calcium phosphorus mineralized layer superfine fibre bone material of the present invention comprises:
(1) electricity spins the preparation of solution: use solvent and electric woven material compound concentration to spin solution as the electricity of 6%-15%;
(2) electrostatic spinning prepares superfine fibre: the electricity that will prepare spins solution packs in the electrostatic spinning apparatus, and the electricity spinning is equipped with polymer superfine fibre, and the control electricity spins parameter, makes the fiber surface of preparation uniform and smooth; Collect superfine fibre with stainless steel electrode or platinum electrode, the pole piece and the support section of electrode are detachable, and electrode slice uses through polishing with after cleaning, and guarantees that the mineralising superfine fibre is easy to separate from pole piece;
(3) preparation of electric depositing solution: with proper C a (NO
3)
2And NH
4H
2PO
4Two kinds of materials join mix homogeneously in the deionized water respectively, and with the pH value of ammonia and hydrochloric acid conditioning solution, obtaining concentration is the Ca (NO of 0.01～0.2mol/L
3)
2Solution, concentration are the NH of 0.01～0.05mol/L
4H
2PO
4Solution, the pH value of solution are 3.1～5.2;
(4) electrochemical deposition of electrospinning fibre: with the stainless steel electrode that covers superfine fibre film is that negative electrode, platinum electrode are anode, adding electric depositing solution; Water bath with thermostatic control control electrodeposition temperature is 30～70 ℃, constant voltage-1.5～-3.0V, constant current 0.1～10mA/cm
2Deposition; Electrode distance is 1.5～3cm, and sedimentation time is 15～120min, makes the calcium microcosmic salt pattern even compact, structurally ordered of generation; The mineralising superfine fibre of preparation takes off from electrode to be rinsed well; Through 0.1～1.0mol/LNaOH solution soaking, 1～24h, make synthos partly be converted into hydroxyapatite (HA), clean the back and in air, dry;
(5) machine-shaping of porous bone material:, be the NH of 1:0.5-1 again with mol ratio with range upon range of the adding up of mineralising superfine fibre 50-100 of preparation
4HCO
3And the even spreading of mixture of two kinds of salt of NaCl (particle diameter is controlled at 100～500 μ m) with being placed in the stainless steel mould, is cast into bulk at room temperature, 10～40MPa between each layer fiber, places 60～90 ℃ hot water to soak about 5～30min, NH material
4HCO
3Decomposes discharges ammonia and carbon dioxide is overflowed from material, on material, forms micron-sized aperture, places 50～70 ℃ of water-baths to soak 10～30min bulk material again, removes remaining NaCl particle, and last bone material is in-5～-20 ℃ of following lyophilizing;
(6) sterilization and packing: the bone material of above-mentioned preparation encapsulates with double-layer polyethylene film, and oxirane disinfection is preserved subsequent use after 2～4 hours.
The electric woven material of said step (1) comprises various natural, synthetic polymers and both complex.
Described natural polymer comprises native protein, polysaccharide and composites thereof such as collagen protein, elastin laminin, gelatin, fibroin albumen, Fibrinogen, vegetable protein, hyaluronic acid, chitosan, Bacterial cellulose; Synthetic polymer comprises and gathers Acetic acid, hydroxy-, bimol. cyclic ester, polylactide, polycaprolactone, poe, gathers anhydride, polyglycolic acid and various copolymer thereof.
Said step (1) solvent is selected from oxolane, dehydrated alcohol, acetic acid, hexafluoroisopropanol, acetone, trifluoroethanol, dichloromethane, chloroform, N, the mixed solvent of one or more in the dinethylformamide.
The electric spinning method of said step (2) comprises the single nozzle electrospinning of employing, coaxial cospinning and mixes electrospinning, preparation one pack system, skin-core, compound superfine fibre.
It is that voltage is 16.0-25KV that said step (2) electricity spins parameter; Receiving range is 15.0cm-20.0cm; Feed flow speed is 1.2ml/h-2ml/h, and PLLA (PLLA) fibrous membrane of the thick about 0.1mm of 30min rear electrode surface coverage changes the PLLA fibrous membrane that the electrode another side receives same thickness.
The porosity of said step (5) porous bone material is controlled at 50～90%, and pore diameter range is controlled to be 50～500 μ m;
The main component of described calcium phosphorus mineralized layer is brushite and hydroxyapatite.
The calcium phosphorus mineralized layer superfine fibre bone material of above-mentioned preparation adopts salt grain leaching/gas foaming technology to be processed into the porous bone holder material, to be used for bone defect repair clinically.
The electric-woven super-fine fiber that relates among the present invention is meant the nanometer, submicron or the micron order that adopt medically acceptable any material electricity spinning to be equipped with (diameter 0.1 nanometer to 10 micron) fiber, and the difference of spinning processing mode according to electricity can obtain one-component, skin-core, the different composition and the superfine fibre of fine structure such as compound.
The porous bone material that the present invention is prepared because of bone mineral has special preferred orientation property in electrochemical deposition process, is similar to the bone ore deposit composition that the nature bone forming process produces to a certain extent, has better biocompatibility.Electrochemical deposition technique is used for the biomineralization of electric-woven super-fine fiber; Can prepare the composite organic-inorganic material that contains higher mineralogical composition in the short period of time; Because preparation time is short and mild condition, can not cause that the bioactive ingredients that loads in the superfine fibre discharges and inactivation in advance.For reaching the purpose of treatment and healing acceleration, in electrospinning fibre, can add various bioactive ingredients, comprise various curative drugs, antibiotic, somatomedin, oligonucleotide, polynucleotide etc.
Beneficial effect
(1) the porous bone material of the present invention's preparation is similar to the bone ore deposit composition that the nature bone forming process produces to a certain extent, has the compatibility preferably;
(2) the present invention's porous bone material here has appropriate bore gap structure and mechanical property;
(3) the short and mild condition of preparation time of the present invention can not cause that the bioactive ingredients that loads in the superfine fibre discharges and inactivation in advance.
Description of drawings
Fig. 1 is the SEM pattern photo of the PLLA superfine fibre of preparation, and A is that static spins gained PLLA superfine fibre; B is-the 2.0V running voltage under behind the electro-deposition 60min, the cellular calcium microcosmic salt of formation is covered in the fibrous membrane surface;
Fig. 2 is the XRD diffraction spectrogram of sample among the embodiment 1, the commercialization HA particulate XRD diffracting spectrum of A for buying; B is that static spins gained PLLA superfine fibre soaks 60min in electrolyte XRD diffracting spectrum; The back XRD diffracting spectrum of the C electro-deposition 60min that is the PLLA superfine fibre under-2.0V running voltage.After 60 minutes, 2 θ=11.8 on the spectrogram.It is thus clear that obviously sharp peak is the characteristic peak of calcium hydrogen phosphate salt, at 25.8 °, 32 °, HA characteristic peak place is the indefinite form peak, has generated section H A after can knowing 60min in conjunction with the FTIR collection of illustrative plates.So its fiber mineralized layer is calcium hydrogen phosphate salt and HA salt-mixture; Fig. 3 is the FTIR spectrogram of sample among the embodiment 1, the commercialization HA particulate FTIR of A for buying; B is that static spins gained PLLA superfine fibre soaks 60min in electrolyte FTIR; The C FTIR behind the electro-deposition 60min that is PLLA superfine fibre template under-2.0V running voltage.At 1000～1100 (cm
-1) its peak is sharply obvious, is PO
4 3-, H
2PO
4-, HPO
4 2-Absorption region, in conjunction with 870 (cm
-1) locate the peak and XRD result can confirm phosphoric acid hydrogen calcium salt.At 3510cm
-1The hydroxyl characteristic absorption peak of the visible HA in place in conjunction with the XRD characterization result of figure two, shows and contains section H A in the calcium-phosphate layer.
The specific embodiment
Further set forth the present invention below in conjunction with specific embodiment.Should be understood that these embodiment only to be used to the present invention is described and be not used in the restriction scope of the present invention.Should be understood that in addition those skilled in the art can do various changes or modification to the present invention after the content of having read the present invention's instruction, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Embodiment 1
(1) be that the chloroform/acetone of 3:1 is a solvent with the volume ratio, preparation 6% (w/v) PLLA (molecular weight 130,000) electricity spins solution;
(2) choose the platinum electrode of 2cm * 2cm, the surface is through polishing and be used as electricity after cleaning and spin gathering-device, adopts single shower nozzle electrospinning to prepare the PLLA superfine fibre at electrode surface.Adopting 21G entry needle (internal diameter 0.51mm) is spinning head, and HV generator provides high direct voltage, and micro-injection pump carries electricity to spin solution; Electricity spins parameter: voltage is 16.0KV, and receiving range is 15.0cm, and feed flow speed is 1.2ml/h, and the PLLA fibrous membrane of the thick about 0.1mm of 30min rear electrode surface coverage changes the PLLA fibrous membrane that the electrode another side receives same thickness;
(3) preparation 100ml electrolyte, wherein Ca (NO
3)
2The concentration of solution is 0.042mol/L, NH
4H
2PO
4The concentration of solution is 0.025mol/L, and calcium-phosphorus ratio is 1.67 in the solution, and regulating pH value is 4.7.With two-sided collection the platinum electrode of PLLA nanofiber being arranged is negative electrode, and the another platinum electrode is an anode, uses the constant voltage mode to carry out electrochemical deposition; Sedimentary condition: voltage is-2.0V, and electrode distance is 2.5cm, and sedimentation time is 60min; The mineralising nanofiber sample of preparation soaks 2h through 0.1mol/L NaOH, cleans the back and in air, dries subsequent use naturally; The same terms is the mineralising fibrous membrane of 50 same sizes of preparation down;
The 50 lump ore superfine fibre multilamellars that (4) will prepare stack up containing NH
4HCO
3And the even spreading of mixture that two kinds of salt of NaCl (particle diameter 200～300 μ m) are formed is between each layer fiber, will prop up subsequently to be placed in the self-control stainless steel mould, about room temperature, 20MPa, is cast into bulk.Bulk material adopts salt grain leaching/gas foaming technology to process porous material.Promptly place 80～90 ℃ hot water to soak about 10min bulk material earlier, will prop up to be placed in 60 ℃ of water-baths again and soak 20～30min, remove remaining NaCl particle, last support is in-20 ℃ of following lyophilizing;
(5) material of preparation encapsulates with double-layer polyethylene film, and oxirane disinfection is preserved subsequent use after 2 hours.
The PLLA superfine fibre SEM pattern photo see Fig. 1.
Embodiment 2
(1) material therefor is for engraving the type i collagen (molecular weight 0.8～1.0 * 10 that lets Bioisystech Co., Ltd buy from Sichuan
5), the employing hexafluoroisopropanol is a solvent, compound concentration is that the electricity of 8% (w/v) spins solution;
(2) two-sided reception electricity spins collagen fiber on platinum electrode.Electricity spins parameter: voltage is 15KV, and receiving range is 10cm, and feed flow speed is 0.8ml/h, and the single-side electrode time of reception is 30min.Treat that the two-sided collagen fiber of all having collected of electrode are placed in the vacuum drying oven that evacuation 12h removes residual solvent under the room temperature;
All the other prepare mineralized collagen porous bone material with embodiment 1.
Embodiment 3
With embodiment 1, different is to adopt coaxial cospinning (coaxial electrospinning) technology two-sided preparation skin-core electric-woven super-fine fiber on platinum electrode.It is interior pin (internal diameter 0.51mm, external diameter 0.8mm) that coaxial cospinning device in the present embodiment adopts the 21G entry needle, and outer nozzle needle internal diameter is 1.6mm.The about 5mm of the inside indentation of interior nozzle needle mouth.Cortical material adopts 10% (w/v) PLLA electricity to spin solution, core matter adopts the 3%PEO that adds rhBMP-2 (rhBMP-2) (80～100 μ g/mL electricity spin liquid), is that solvent preparation skin, sandwich layer electricity spin solution with chloroform and physiological saline solution respectively.The control output voltage is 18KV during coaxial cospinning, and the liquid supply speed of skin, sandwich layer solution is respectively 3ml/h and 0.4ml/h, and receiving range is 12cm.
All the other same embodiment (1) prepare the porous bone material.
Embodiment 4
With embodiment 1, different is to adopt the mixing electricity to spin (mixing electrospinning) technology two-sided preparation collagen/PLLA composite ultrafine fiber on platinum electrode.In the mixing electricity spun, 8% (w/v) type i collagen and 10% (w/v) PLLA solution deposited on the platinum electrode from two spouts respectively simultaneously, have obtained the composite cellulosic membrane of two kinds of material interlacings.Electricity spins parameter: voltage is 16KV, and receiving range is 10cm, and feed flow speed is 1.5ml/h.
All the other same embodiment (1) prepare the porous bone material.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102021651A CN101406711B (en) | 2008-11-04 | 2008-11-04 | Method for preparing galvanic deposit calcium phosphorus mineralized layer superfine fibre bone material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102021651A CN101406711B (en) | 2008-11-04 | 2008-11-04 | Method for preparing galvanic deposit calcium phosphorus mineralized layer superfine fibre bone material |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101406711A CN101406711A (en) | 2009-04-15 |
| CN101406711B true CN101406711B (en) | 2012-11-07 |
Family
ID=40570053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102021651A Expired - Fee Related CN101406711B (en) | 2008-11-04 | 2008-11-04 | Method for preparing galvanic deposit calcium phosphorus mineralized layer superfine fibre bone material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101406711B (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101601871B (en) * | 2009-05-27 | 2013-01-23 | 天津大学 | Bionic bone repair material of mineralized electro-spinning gelatin superfine fibers and preparation method thereof |
| DE102010025533B4 (en) | 2010-06-29 | 2014-09-04 | Heraeus Medical Gmbh | Procedure for bone growth promoting coating |
| DE102010055561B4 (en) | 2010-12-23 | 2015-12-31 | Heraeus Medical Gmbh | Coating method and coating device |
| CN103402559A (en) * | 2011-02-28 | 2013-11-20 | 太阳星光齿磨公司 | Non-woven fabric containing bone prosthetic material |
| CN103046225B (en) * | 2012-01-19 | 2015-12-02 | 苏州景卓生物技术有限公司 | A kind of preparation method of collagen film |
| WO2014145864A1 (en) | 2013-03-15 | 2014-09-18 | Nanofiber Solutions, Llc | Biocompatible fiber textiles for implantation |
| CN103741262B (en) * | 2013-07-03 | 2016-06-15 | 上海昊海生物科技股份有限公司 | A kind of chitosan nano fibrous membrane for cerebral dura mater or Broken dura remedy and preparation method thereof and application |
| CN103405809B (en) * | 2013-07-23 | 2015-01-21 | 东华大学 | Method used for preparing microcarrier/polymer composite scaffold by electro-deposition |
| CN103463685B (en) * | 2013-08-30 | 2015-05-20 | 西北工业大学 | Preparation method of degradable porous structural tissue engineering bracket with high strength |
| CN103893828B (en) * | 2014-02-28 | 2016-01-20 | 广西医科大学 | A kind of method improving calcium phosphate bone cement toughness |
| CN104060401A (en) * | 2014-07-04 | 2014-09-24 | 东华大学 | Electrostatic spinning preparing method of gelatin nanofiber membrane capable of releasing vitamin A |
| CN104264368B (en) * | 2014-09-23 | 2016-07-13 | 杭州同净环境科技有限公司 | A kind of preparation method of the spontaneous type microorganism attachment fiber that is separated |
| CN104353118B (en) * | 2014-11-05 | 2017-01-25 | 上海师范大学 | Collagenous fiber non-woven hydroxyapatite biological scaffold material |
| CN104963025A (en) * | 2015-06-05 | 2015-10-07 | 李松群 | Coaxial electrospinning process of fibroin-polycaprolactone bi-component ultrafine fiber |
| CN105019004B (en) * | 2015-07-09 | 2017-05-31 | 新疆师范大学 | A kind of preparation method of electrospinning PLLA/Ag antimicrobial compound films |
| CN105148321B (en) * | 2015-08-31 | 2018-01-30 | 中原工学院 | Bone alternate material of bionical natural bony structure that a kind of nanofiber by mineralising is built and preparation method thereof |
| CN105727369B (en) * | 2016-03-21 | 2019-01-08 | 中国科学院化学研究所 | A kind of preparation method of gelatin/Hydroxy apatite bone bracket |
| CN107308492B (en) * | 2017-06-28 | 2018-05-25 | 郭婷 | A kind of preparation method of antibacterial paradenlal tissue regeneration film |
| CN107551328B (en) * | 2017-10-31 | 2021-03-05 | 无锡中科光远生物材料有限公司 | Preparation method of antibacterial and immunoregulation surface functionalized electrostatic spinning membrane for bone regeneration |
| CN107754014A (en) * | 2017-11-29 | 2018-03-06 | 上海纳米技术及应用国家工程研究中心有限公司 | The antibacterial on PET surface promotees preparation method of bone composite coating and products thereof and application |
| CN108982565A (en) * | 2018-05-29 | 2018-12-11 | 四川维思达医疗器械有限公司 | A kind of method of the concentration of electrolyte condition of determining calcium phosphate coating pattern |
| CN112267214B (en) * | 2020-09-18 | 2022-01-25 | 宁波方太厨具有限公司 | Preparation method of electrostatic spinning mineralized nanofiber membrane |
| CN112121228B (en) * | 2020-10-19 | 2021-04-09 | 山东第一医科大学附属省立医院(山东省立医院) | Bone defect cavity filling implant |
| CN115068693B (en) * | 2021-03-11 | 2024-04-12 | 东北林业大学 | A bone repair foaming composite material and preparation method thereof |
| WO2023142599A1 (en) * | 2022-01-27 | 2023-08-03 | 华东理工大学 | Preparation method for collagen material stripped from electrode, and use of collagen material |
| CN115581801B (en) * | 2022-09-29 | 2024-05-17 | 苏州大学 | A calcium phosphate mineralized silk micro-nano fiber membrane and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020029724A1 (en) * | 1988-04-05 | 2002-03-14 | John R. Mott | Fiber composite article and method of manufacture |
| CN1456360A (en) * | 2003-05-28 | 2003-11-19 | 东南大学 | Absorbable superfine fibre tissue remedial materials and preparing method thereof |
| CN101050312A (en) * | 2005-12-16 | 2007-10-10 | 西南交通大学 | Method for preparing biodegradable composite material of calcium, phosphor inorganic biologic particles / macromolecules |
-
2008
- 2008-11-04 CN CN2008102021651A patent/CN101406711B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020029724A1 (en) * | 1988-04-05 | 2002-03-14 | John R. Mott | Fiber composite article and method of manufacture |
| CN1456360A (en) * | 2003-05-28 | 2003-11-19 | 东南大学 | Absorbable superfine fibre tissue remedial materials and preparing method thereof |
| CN101050312A (en) * | 2005-12-16 | 2007-10-10 | 西南交通大学 | Method for preparing biodegradable composite material of calcium, phosphor inorganic biologic particles / macromolecules |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101406711A (en) | 2009-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101406711B (en) | Method for preparing galvanic deposit calcium phosphorus mineralized layer superfine fibre bone material | |
| Chae et al. | Novel biomimetic hydroxyapatite/alginate nanocomposite fibrous scaffolds for bone tissue regeneration | |
| Phipps et al. | Increasing the pore sizes of bone-mimetic electrospun scaffolds comprised of polycaprolactone, collagen I and hydroxyapatite to enhance cell infiltration | |
| Li et al. | Biomimicry, biomineralization, and bioregeneration of bone using advanced three-dimensional fibrous hydroxyapatite scaffold | |
| CN102166378B (en) | Tissue regeneration guiding membrane and preparation method thereof | |
| CN102049066B (en) | Magnetic composite material and application thereof in regeneration and repair of bone tissues | |
| CN105435311B (en) | A kind of tissue engineered bone cartilage compound rest and preparation method thereof | |
| WO2011026323A1 (en) | Artificial neural implant prepared by electrostatic spinning, preparation method and special device therefor | |
| CN101856510B (en) | Preparation method of composite nano-fiber support material of silk fibroin and calcium silicate | |
| CN110935059A (en) | MXene composite bone repair material with photothermal function and preparation method thereof | |
| Sheikh et al. | A simple approach for synthesis, characterization and bioactivity of bovine bones to fabricate the polyurethane nanofiber containing hydroxyapatite nanoparticles | |
| CN113786516A (en) | PCL/Col/MC gradient three-layer artificial periosteum and preparation method and application thereof | |
| CN102605460A (en) | Silk fibroin/hydroxyapatite nanofiber material and preparation method thereof | |
| Oprea et al. | Electrospun nanofibers for tissue engineering applications | |
| CN107670115A (en) | Fibroin albumen/hydroxyapatite/poly-（Racemic lactic acid co caprolactones）The preparation method of composite nano-fiber membrane | |
| CN111529759A (en) | A macroporous bone tissue engineering scaffold capable of continuously releasing inorganic active components and preparation method thereof | |
| CN102139125A (en) | Growth-factor-containing nanofibre porous composite material capable of repairing bone and preparation method thereof | |
| CN103638561B (en) | Preparation method of micro-nano bioactive porous material | |
| CN101954118B (en) | Method for preparing aqueous gel/nano hydroxyapatite composite scaffold for hard tissue repair | |
| CN114681668B (en) | Preparation method of 3D printed selenium-doped hydroxyapatite artificial bone structure | |
| Hu et al. | Cell electrospinning and its application in wound healing: principles, techniques and prospects | |
| CN106012297B (en) | A kind of preparation method of medical composite fibre three-dimensional structure dressing | |
| CN114028620B (en) | Mineralized artificial periosteum and preparation method and application thereof | |
| CN105664240A (en) | Preparation method of bionic nanofiber scaffold with electrical stimulation effects | |
| Liu et al. | Artificial osteochondral interface of bioactive fibrous membranes mediating calcified cartilage reconstruction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121107 Termination date: 20151104 |
|
| EXPY | Termination of patent right or utility model |